What Simplified Consent Does and Does Not Permit

Part of Consent and Vulnerable Populations: Cluster Trials and Simplified Consent.

About 5 minutes. Free, in your language, no account needed.

Why this matters

Simplified consent is a real provision with a narrow scope, and it is attractive to study teams for reasons that have nothing to do with its purpose. Obtaining individual written consent from thousands of people is expensive and slow, and a provision that reduces it is welcome.

That attraction is precisely why the scope needs to be understood exactly. A trial that adopts simplified consent because full consent is burdensome, rather than because the trial meets the conditions, has not simplified a process. It has proceeded without the consent the framework requires.

What "simplified" changes

It changes the mechanism of consent, not its existence.

Depending on the framework and what the member state permits, simplification may mean information provided in a different form, consent obtained other than in writing, consent obtained from a representative of the cluster in defined circumstances, or a process based on notification and the opportunity to object rather than an affirmative signature.

What it does not change: the participant must be informed, and the participant must not object. A process that leaves participants uninformed is not simplified consent. It is no consent.

The conditions, and why each is there

Under Regulation (EU) No 536/2014 the conditions for simplified means in cluster trials include:

The methodology requires allocation of groups rather than individuals. The design must genuinely need it. A trial that could have allocated individuals and chose clusters for convenience does not qualify.

The trial is low-intervention. Defined in the Regulation, and it carries real limits.

The medicinal products are used in accordance with the terms of the marketing authorization, so participants receive products as they would in routine care.

No procedures additional to normal clinical practice apply. This is the condition that most often excludes a trial from the category, because research almost always adds something: an extra assessment, a questionnaire, an additional sample.

The member state concerned permits it. This is not automatic across the European Union, and it must be checked per member state rather than assumed.

The subject does not object. Objection remains available and must be respected, which requires the participant to know enough to be in a position to object.

The conditions read together

Taken together they describe a narrow class: a trial comparing approaches that are all already standard, using authorized products as authorized, adding nothing to what would happen anyway, allocated by cluster because the question requires it.

That trial genuinely does not need the full apparatus of individual written consent, because nothing is happening to any participant that would not have happened.

As soon as something is added, the trial leaves the category. A single extra blood sample takes it out. An unauthorized product takes it out. A procedure done for research takes it out.

What must still happen

Even within the category:

Participants must be informed that the research is happening, in a way they will actually encounter. A notice on a wall nobody reads does not inform anyone.

Objection must be genuinely available, which means a route that is easy, known, and does not require confronting anyone.

An objection must be respected and must be recorded.

Data protection obligations continue unchanged. Simplified consent under a medicines framework does not simplify anything about lawful processing of personal data, which is a separate body of law with its own requirements.

That last point catches teams out regularly. The two frameworks are independent, and satisfying one says nothing about the other.

In practice

A team proposes a cluster trial comparing two authorized medicines already used for a condition, with practices allocated to a preferred first-line choice.

The initial design includes a quality of life questionnaire at three months.

The regulatory lead points out that the questionnaire is a procedure additional to normal clinical practice, which takes the trial outside the simplified consent conditions in the member states where those conditions apply.

Two options. Remove the questionnaire and use routine data only, keeping the trial within the category. Or keep it and obtain full individual consent from participants who complete it.

The team chooses the second, with a two-tier process: notification and opt-out for the routine data, and full written consent for the questionnaire subset.

The trial keeps its secondary endpoint and the consent mechanism matches what is actually being asked at each level.

What this looks like when it goes wrong

A cluster trial adopts simplified consent on the basis that it compares two standard approaches.

The protocol includes a research blood sample at baseline and at six months.

The samples are additional to normal clinical practice. The trial does not meet the conditions, and the ethics committee approved it on a description that emphasized the comparison of standard approaches and mentioned the samples in a later section.

Nobody misrepresented anything deliberately. The application described the trial accurately across several sections, and the conclusion that it qualified for simplified consent was reached by someone reading the parts that supported it.

Two thousand participants have had research blood samples taken under a consent mechanism that does not cover research procedures, and the remedy is not available retrospectively.

Key takeaways